Journal of Pulmonology and Respiratory Diseases
Open Access

Idiopathic pneumonic pathology (IPF) may be a cryptogenic chronic respiratory disorder with progressive pathology and a poor prognosis. A substantial number of epidemiologic studies are conducted in Europe and also the United States (US). In contrast, in Japan, only 1 study reportable the prevalence of IPF (10.0 per 100,000 population) victimization clinical information (2003–2007) from one prefecture; therefore, the nationwide prevalence of IPF remains unknown. This study aimed to estimate the nationwide prevalence of IPF in Japan employing nationwide claims information.

We extracted information from a Japanese claims info provided by Medical information Vision (MDV info, April 2008–March 2019) containing information from around 28 million patients from 385 acute-care hospitals. Patients with IPF (those diagnosed with IPF a minimum of once) from April 2017 to March 2018 were known within the MDV information [1]. The quantity of patients within the MDV information was cypher nationwide victimization the fourth NDB Open information (April 2017–March 2018), and also the prevalence was calculable victimization demographic information as denominators. The prevalence within the United States of America, considering an equivalent definition of IPF, was conjointly calculated and compared with that in Japan.

We report the nationwide IPF prevalence in Japan victimization information from claims databases for the primary time [2]. The prevalence calculable during this study was on top of that reportable during a previous study. The distinction could be because of variations in study settings and definitions of IPF. Additional analysis ought to be performed to see the prevalence additional accurately and compare it with those in different countries.

Idiopathic pneumonic pathology (IPF) is a cryptogenic chronic interstitial pneumonia with progressive fibrosis and poor prognosis that mainly develops in older people. Primary symptoms at the onset of the disease dry cough and exertion dyspnea. The median patient survival time is reportedly 2–5 years when initial diagnosing. International standards for the diagnosing and treatment of IPF are outlined in the guidelines generated in 2011 and revised in 2015 and 2018 by The American Thoracic Society, The European Respiratory Society, The Japanese Respiratory Society, and The Latin American Thoracic Association [3].

One of the Japanese databases is maintained by Medical information Vision Co., Ltd. (hereafter the MDV database; April 2008– March 2019), that contains the claims information of roughly 28 million patients from 385 diagnosing procedure combination-designated acute care hospitals, termed DPC hospitals (as of August 2019). The MDV info enclosed the info of all patients visiting the corresponding hospitals in spite of the patients’ age and sort of insurance. Because the database didn't contain population information and therefore the prevalence couldn't be calculable only from these information, we have a tendency to used two further information sources [4]. We have a tendency to used NDB Open information (fourth NDB Open Data: April 2017–March 2018) to estimate the nationwide range of patients and used demographic information as denominators. NDB Open information may be a publically out there outline computer programmes from the National info of insurance Claims and Specific Health Checkups of Japan (NDB) revealed by the Ministry of Health, Labour and Welfare. The NDB contains the majority insurance claims information and specific health health check information related to the national insurance system. Within the NDB Open information, a 100 of the foremost pharmaceuticals for every therapeutic class during a 1-year amount from April are summarized for every age and sex cluster. Pirfenidone, that is one of two ant fibrotic medicine (along with nintedanib) suggested as first-line treatments within the pointers, is enclosed within the fourth NDB Open information [5].

This study calculable the nationwide prevalence of IPF in Japan by developing a technique combining information from multiple sources. To the simplest of our data, this can be the primary study to research the nationwide prevalence of IPF in Japan. The calculable prevalence was 27 per 100,000 population. The age bracket with the very best prevalence was 75–79 years in both sexes. Compared therewith within the United States of America, the prevalence was similar in men and comparatively lower in ladies till the age of 75–79 years, whereas it had been notably lower in each sexes aged ≥ 80 years.

This study reportable the nationwide IPF prevalence in Japan victimization information from claims databases. The prevalence in Japan was calculable to be 27 per 100,000 population that was on top of that reportable in previous studies. The distinction could be because of variations within the definitions of IPF and also the settings of the studies. The prevalence in Japan was below that within the United States of America, significantly in patients aged ≥ 80 years. Additional analysis ought to be performed to see the prevalence additional accurately and compare it therewith in different countries.

1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, et al. (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199-203.

Indexed at, Google Scholar, Crossref

2. Gribbin J, Hubbard R, Smith C (2009) Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 103: 927-931.

Indexed at, Google Scholar, Crossref

3. D.A. Zisman, S.M. Kawut (2008) Idiopathic pulmonary fibrosis: a shot through the heart?. Am J Respir Crit Care Med 178: 1192-1193.

Indexed at, Google Scholar, Crossref

4. Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, et al. (1994) Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med 149: 1583-1590.

Indexed at, Google Scholar, Crossref

5. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, et al. (2005)  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128: 2393-2399.

Indexed at, Google Scholar, Crossref